Loading
Loading
Research Overview
Essential coenzyme in redox metabolism; serves as a substrate for sirtuins (SIRT1–7), PARP enzymes, and CD38, all of which regulate energy homeostasis, DNA repair, and cellular stress responses. NAD+ levels decline ~50% between 40–60 years of age.
Overview
NAD+ is a dinucleotide coenzyme that serves as an electron acceptor in glycolysis and the TCA cycle, cycling between oxidised (NAD+) and reduced (NADH) forms to transfer electrons to the mitochondrial electron transport chain. Beyond its role as an electron carrier, NAD+ is consumed as a substrate by three major enzyme families: sirtuins (NAD+-dependent deacylases implicated in metabolic gene regulation and ageing), PARPs (poly ADP-ribose polymerases involved in DNA repair), and CD38 (a cyclic ADP-ribose hydrolase involved in calcium signalling). Preclinical research has studied how NAD+ availability influences these enzyme activities and their downstream biological consequences.
A major focus of NAD+ preclinical research has been the relationship between declining NAD+ levels and ageing biology. Animal model studies have documented decreased tissue NAD+ concentrations with advancing age across multiple tissues, and have used supplementation and biosynthetic pathway modulation to examine whether restoring NAD+ levels influences ageing-associated phenotypes in laboratory model systems.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, nad+ (nicotinamide adenine dinucleotide) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Essential coenzyme in redox metabolism; serves as a substrate for sirtuins (SIRT1–7), PARP enzymes, and CD38, all of which regulate energy homeostasis, DNA repair, and cellular stress responses. NAD+ levels decline ~50% between 40–60 years of age.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
